Nasus Pharma LTD (NSRX) — SEC Filings

Overview

Nasus Pharma LTD (NSRX) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a EFFECT filed on Apr 1, 2026: Nasus Pharma Ltd. filed an EFFECT form with the SEC on April 1, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-293950. The effectiveness date is March 31, 2026. The company's mailing and business address is 29 Harakevet St, Tel Aviv-Yafo, Israel.

Sentiment Summary

Across 17 filings, the sentiment breakdown is: 1 bullish, 1 bearish, 14 neutral, 1 mixed. The dominant filing sentiment for Nasus Pharma LTD is neutral.

Filing Type Overview

Nasus Pharma LTD (NSRX) has filed 5 3, 1 EFFECT, 10 6-K, 1 20-F with the SEC between Aug 2025 to Apr 2026.

Filings by Year

2026 · 2025

Recent Filings (17)

• Nasus Pharma Ltd. Filing Effectiveness Noted by SEC — EFFECT · Apr 1, 2026 Risk: low
  Nasus Pharma Ltd. filed an EFFECT form with the SEC on April 1, 2026, indicating the effectiveness of a filing related to Act 33, File No. 333-293950. The effec
• 3 Filing — 3 · Mar 28, 2026
• Nasus Pharma Ltd. Files Initial Ownership Statement — 3 · Mar 28, 2026 Risk: low
  On March 27, 2026, Nasus Pharma Ltd. (CIK: 0002029039) filed an initial statement of beneficial ownership of securities (Form 3). The filing pertains to the per
• 3 Filing — 3 · Mar 28, 2026
• Nasus Pharma Ltd. Files Initial Ownership Statement — 3 · Mar 28, 2026 Risk: low
  On March 27, 2026, Nasus Pharma Ltd. (CIK: 0002029039) filed a Form 3, an initial statement of beneficial ownership of securities. The filing pertains to the pe
• 3 Filing — 3 · Mar 28, 2026
• Nasus Pharma Files Routine 6-K Foreign Issuer Report — 6-K · Mar 25, 2026
  Nasus Pharma Ltd. filed a 6-K report on March 25, 2026, indicating a routine foreign issuer report. This filing, with accession number 0001493152-26-012663, inc
• Nasus Pharma Faces Going Concern Doubt Amidst Clinical Development Push — 20-F · Mar 25, 2026 Risk: high
  Nasus Pharma Ltd. (NSRX) is a clinical-stage specialty pharmaceutical company focused on intranasal drugs for emergency medical conditions. The company has not
• 6-K Filing — 6-K · Dec 29, 2025
• 6-K Filing — 6-K · Dec 22, 2025
• Nasus Pharma Appoints New CFO — 6-K · Nov 20, 2025 Risk: low
  On November 19, 2025, Nasus Pharma Ltd. appointed Eyal Rubin as its new Chief Financial Officer (CFO) and Executive Vice President. The company entered into an
• Nasus Pharma Doses First Patient in NS002 Phase 2 Study — 6-K · Nov 18, 2025 Risk: medium
  Nasus Pharma Ltd. announced on November 18, 2025, the initiation of a Phase 2 clinical study for its drug candidate NS002. The first participant has been dosed,
• Nasus Pharma Ltd. Updates Corporate Presentation — 6-K · Nov 3, 2025 Risk: low
  On November 3, 2025, Nasus Pharma Ltd. made available an updated corporate presentation on its website. This presentation is attached as Exhibit 99.1 to their F
• Nasus Pharma Extends Aptar Collaboration for Epinephrine Program — 6-K · Oct 8, 2025 Risk: medium
  On October 6, 2025, Nasus Pharma Ltd. extended its collaboration with AptarGroup, Inc. to advance the development and commercialization of its intranasal Epinep
• Nasus Pharma Ltd. Closes Partial Over-Allotment Option Exercise — 6-K · Sep 30, 2025 Risk: low
  On September 30, 2025, Nasus Pharma Ltd. partially exercised its IPO over-allotment option, selling an additional 3,824 ordinary shares at $8.00 per share. The
• Nasus Pharma CEO Joins Board of Directors — 6-K · Sep 5, 2025 Risk: low
  On September 3, 2025, Nasus Pharma Ltd. appointed its CEO, Dan Teleman, to fill a vacancy on its Board of Directors. Mr. Teleman will serve as a Class III direc
• Nasus Pharma Closes Initial Public Offering — 6-K · Aug 14, 2025 Risk: medium
  On August 14, 2025, Nasus Pharma Ltd. announced the closing of its Initial Public Offering (IPO). The company, headquartered in Tel Aviv, Israel, filed this rep

Risk Profile

Risk Assessment: Of NSRX's 11 recent filings, 1 were flagged as high-risk, 3 as medium-risk, and 7 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Key Executives

• David Silberman
• 0001867998
• Gilboa Udi
• Dan Teleman
• Eyal Rubin

Industry Context

The specialty pharmaceutical sector is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often focus on niche therapeutic areas or novel delivery mechanisms, like Nasus Pharma's intranasal approach. The competitive landscape includes established pharmaceutical giants and numerous clinical-stage biotechs, all vying for market share and investor capital.

Top Tags

ownership (2) · ipo (2) · filing-effectiveness (1) · sec-filing (1) · pharmaceutical (1) · insider-filing (1) · initial-filing (1) · sec-form-3 (1) · regulatory-filing (1) · foreign-issuer (1)

Key Numbers

• Filing Acceptance Date: 2026-04-01 — Date the SEC accepted the filing.
• Effectiveness Date: 2026-03-31 — Date the filing became officially effective.
• File Number: 333-293950 — Specific SEC file number associated with the filing.
• Ordinary Shares outstanding: 9,015,383 — as of December 31, 2025
• healthy adults: 50 — participating in NS002 Phase 2 study in Canada
• planned initiation of additional Phase 2 study for NS002: Q2 2026 — evaluating self-administration
• planned IND submission for NS002: Q3 2026 — following completion of additional Phase 2 studies
• planned initiation of pivotal Phase 3 study for NS002: Q4 2026 — prior to FDA marketing approval submission
• exchange rate to $1.00 USD: NIS 3.19 — as of December 31, 2025
• Net Proceeds from Option Exercise: $28 thousand — Additional funds raised by Nasus Pharma from the partial exercise of the over-allotment option.
• Total IPO Net Proceeds: $10.3 million — The aggregate net proceeds raised by Nasus Pharma from its initial public offering.
• Additional Shares Sold: 3,824 — The number of shares issued as part of the over-allotment option exercise.

Frequently Asked Questions